---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000027"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:54:14.837148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris reports Q4 product revenue $32.5M (+52% YoY); guides 2023 revenue $135-165M, cash flow breakeven Q4 2023

## Summary
- Q4 net product revenue $32.5M, up 52% YoY; full-year 2022 net product revenue $109.3M, up 38% pro forma.
- Q4 net loss $12.9M ($0.10/sh); full-year net loss $94.7M ($0.70/sh). Cash at Dec 31, 2022: $122.0M.
- 2023 guidance: total revenue $135M-$165M, cash utilization $57-77M, year-end cash $45-65M; targets cash flow breakeven in Q4 2023.
- Announced research collaboration with Horizon Therapeutics for XeriJect formulation of TEPEZZA; $2.75M upfront payment.
- Gvoke NRx market share >28% at Feb 2023; Recorlev granted FDA orphan-drug exclusivity.

## SEC filing metadata
- accession: 0001867096-23-000027
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/0001867096-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/xers-20230308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000027
- JSON: https://secwatch.observer/filing/0001867096-23-000027.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000027.txt

## Key facts
- Earnings Releases
  Xeris Biopharma Holdings, Inc. updated its the fourth quarter and full-year 2022 guidance (initiated).
  - Period: the fourth quarter and full-year 2022
  - Guidance: initiated
  - Result: reported results
  source text: Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/0001867096-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.